Norges Bank’s scPharmaceuticals SCPH Stock Holding History

Norges Bank’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9,000	Closed	-$109K	–	2160
2017 Q4	$109K	Buy	+9,000	New	+$127K	﹤0.01%	2110

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Norges Bank's SCPH Position: Q1 2018 in Review

Norges Bank sold out of scPharmaceuticals (SCPH) in Q1 2018, closing a stake of 9,000 shares — an estimated $109K sold.

Norges Bank first reported a position in SCPH in Q4 2017 and held it in 1 quarter. The position peaked at $109K in Q4 2017. 38 funds tracked by Wall St. Rank hold SCPH as of Q1 2018.

Norges Bank reported no remaining scPharmaceuticals position as of Q1 2018 after selling out during the quarter.
Norges Bank sold 9,000 scPharmaceuticals shares in Q1 2018, an estimated $109K.
Norges Bank first reported a position in scPharmaceuticals in Q4 2017 and held it in 1 quarter.
Norges Bank's scPharmaceuticals position peaked at $109K in Q4 2017.
38 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2018.

Based on Norges Bank's 13F filing for Q1 2018, filed 9 May 2018.